{"id":"W2967350775","doi":"10.1016/s1470-2045(19)30413-9","title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":780,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University of Calgary","funders":"Cilag; Foundation Medicine; Pharmacyclics; EMD Serono; Genentech; Astellas Pharma; Eisai; Jounce Therapeutics; Acceleron; Chugai Pharmaceutical; Horizon Pharma; National Cancer Institute; Intuitive Surgical; Gilead Sciences; Calithera Biosciences; Celldex Therapeutics; Ipsen; Array BioPharma; Center for Outcomes Research and Evaluation, Yale School of Medicine; Bayer HealthCare; Society of Memorial Sloan Kettering; Exelixis; Sanofi; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Agilent Technologies; Amgen; Pfizer","keywords":"Nivolumab; Sunitinib; Ipilimumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Carcinoma; First line; Randomized controlled trial; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005946273,0.001180867,0.00312361,0.0004480479,0.0005479439,0.001198729,0.0009334628,0.001567861,0.004074327],"category_scores_gemma":[0.004881198,0.0005123279,0.003404346,0.0005074871,0.0009977539,0.001108608,0.0004852888,0.002499858,0.0005774807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001092243,"about_ca_system_score_gemma":0.001395365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007385971,"about_ca_topic_score_gemma":0.001832973,"domain_scores_codex":[0.997306,0.001844848,0.000185155,0.0002952221,0.0001567331,0.00021218],"domain_scores_gemma":[0.9968003,0.001025465,0.0009890953,0.0003271051,0.0001922955,0.0006657275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9870651,0.002388248,0.0007988733,0.0003359046,0.000957919,0.00002404144,0.00003849289,0.000226756,0.001075235,0.00003174744,0.0002519061,0.006805859],"study_design_scores_gemma":[0.9307785,0.06342169,0.00391834,0.00003146058,0.0007829666,0.00003866232,0.00001321339,0.0002782533,0.0002820796,0.00011674,0.0003234175,0.0000146923],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899594,0.004669338,0.0004459788,0.0003473214,0.0003197402,0.00254057,0.0007597005,0.00007593924,0.0008819809],"genre_scores_gemma":[0.9931463,0.001220756,0.0007825195,0.0004381393,0.0003032302,0.002597926,0.0006970653,0.00001421118,0.000799932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005946273,"threshold_uncertainty_score":0.03144729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06296786444902643,"score_gpt":0.3424189717806109,"score_spread":0.2794511073315845,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}